OakChart

Contineum Therapeutics Inc

CTNMHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:34 PM ET

10.79+0.23 (2.18%)
2026-11-11 21:35 CET
Market cap
414.65 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-63.46 USD m
Free cash flow, TTM
-52.03 USD m
EPS diluted, TTM
-1.77
P/E
-
Compare

Price

CTNM against its 20, 50 and 200-day averages
2050200beat
7.5010.0012.5015.0017.504.2M8.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CTNMclose 10.7920-day 9.0050-day 11.58200-day 13.4510.7952w high52w low

39.3% under the 52-week high of 17.79 on 3 Sep 2026. 52-week low 6.73 on 19 Oct 2026. Last 15 sessions, 36.1% high to low

Volume 0.24× normal · the line is the 50-bar volume average

Profile

CTNM
52-week range, 37% of the way up
6.7217.78

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.

IndexRUT
Employees51
IPOApr 05, 2024
Beta0.98
ATR, 14d0.88
Rel volume0.24
Short float11.64%
Insider own19.09%
Inst own78.10%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap423.68M
Enterprise Value185.47M
Income-63.46M
Sales0.00M
Book/sh6.25
Cash/sh6.23
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees51
IPOApr 05, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.73
P/C1.73
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio31.11
Current Ratio31.11
Debt/Eq0.03
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.77
EPS next Y-2.10
EPS next Q-0.51
EPS this Y17.74%
EPS next Y-17.44%
EPS next 5Y2.24%
EPS past 3/5Y-30.91% -
Sales past 3/5Y- -
EPS Y/Y TTM21.55%
Sales Y/Y TTM-
EPS Q/Q-7.03%
Sales Q/Q-
EarningsNov 03 AMC
EPS/Sales Surpr.-7.98% -

Ownership

Insider Own19.09%
Insider Trans-0.93%
Inst Own78.10%
Inst Trans7.64%
ROA-28.34%
ROE-29.80%
ROIC-25.49%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2019.92%
SMA50-6.86%
SMA200-19.76%
Trades-

Technical

Shs Outstand35.34M
Shs Float31.77M
Short Float11.64%
Short Ratio4.43
Short Interest3.70M
52W High17.78 -39.33%
52W Low6.72 60.45%
Volatility10.94% 9.90%
ATR (14)0.88
RSI (14)55.98
Beta0.98
Rel Volume0.24
Avg Volume835.21K
Volume189,559

Performance

Perf Week10.21%
Perf Month28.15%
Perf Quarter-29.48%
Perf Half Y-23.75%
Perf YTD-5.60%
Perf Year-1.55%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.50
Target Price21.43
Prev Close10.56
Price10.79
Change %2.18%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Oct 13, 2026DowngradeRRobert W. BairdOutperform → Neutral$14+29.7%
Jan 08, 2026DowngradeMMorgan StanleyOverweight → Equal-Weight$14+29.7%
Nov 13, 2025InitiatedLLeerink PartnersOutperform$22+103.9%
Sep 25, 2025InitiatedLLeerink PartnersOutperform$20+85.4%
Jun 20, 2025InitiatedWWilliam BlairOutperform
Oct 22, 2024InitiatedRRobert W. BairdOutperform$32+196.6%
Apr 30, 2024InitiatedSStifelBuy$29+168.8%
Apr 30, 2024InitiatedRRBC Capital MktsOutperform$30+178.0%
Apr 30, 2024InitiatedMMorgan StanleyOverweight$25+131.7%

Peers

Mkt cap
TickerCompanyMkt cap
PLRXPliant Therapeutics Inc48.44M
AVLNAvalyn Pharma Inc1.39B
IMUXImmunic Inc110.92M
VCREVicore Pharma Holding AB ADR321.59M
PRTAProthena Corp Plc447.25M
ALECAlector Inc401.67M
DNLIDenali Therapeutics Inc3.18B
ABOSAcumen Pharmaceuticals Inc16.81M
LTGOLatigo Biotherapeutics Inc916.02M
SPTXSeaport Therapeutics Inc1.13B

Insider trading

latest 14 of 65
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Daniel LorrainOfficerNov 04 '26Proposed Sale9.694,17040,407Nov 04 04:22 PM
Daniel LorrainOfficerOct 01 '26Proposed Sale13.424,17055,961Oct 01 04:21 PM
Stengone Carmine N.CEO and PresidentSep 08 '26Option Exercise1.012,5002,52519,717Sep 08 06:08 PM
Stengone Carmine N.CEO and PresidentSep 08 '26Sale16.462,50041,14217,217Sep 08 06:08 PM
CARMINE STENGONEDirectorSep 08 '26Proposed Sale16.702,50041,750Sep 08 04:28 PM
Daniel LorrainOfficerSep 01 '26Proposed Sale16.249,520154,605Sep 01 04:35 PM
Stengone Carmine N.CEO and PresidentAug 03 '26Option Exercise1.012,5002,52519,717Aug 03 06:14 PM
Stengone Carmine N.CEO and PresidentAug 03 '26Sale16.012,50040,02917,217Aug 03 06:14 PM
CARMINE STENGONEDirectorAug 03 '26Proposed Sale15.492,50038,725Aug 03 04:19 PM
Daniel LorrainOfficerAug 03 '26Proposed Sale15.499,520147,465Aug 03 04:18 PM
Lorrain Daniel S.Chief Scientific OfficerJul 08 '26Option Exercise1.011,0151,025136,217Jul 10 05:20 PM
Lorrain Daniel S.Chief Scientific OfficerJul 09 '26Option Exercise1.012525135,227Jul 10 05:20 PM
Lorrain Daniel S.Chief Scientific OfficerJul 08 '26Sale16.001,01516,240135,202Jul 10 05:20 PM
Lorrain Daniel S.Chief Scientific OfficerJul 09 '26Sale16.0025400135,202Jul 10 05:20 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 126

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-0.490-0.454-0.4900.000.008
2026Q22026-07-30-0.400-0.449-0.4040.000.007
2026Q12026-05-05-0.390-0.532-0.3870.000.007
2025Q42026-03-05-0.490-0.389-0.4910.007.507
2025Q32025-10-30-0.450-0.484-0.4550.006.008
2025Q22025-08-05-0.620-0.440-0.6190.007.507
2025Q12025-05-14-0.620-0.565-0.6180.000.006
2024Q42025-03-06-0.560-0.428-0.5630.000.005
2024Q32024-11-06-0.400-0.410-0.3990.000.005
2024Q22024-08-13-0.390-0.348-0.3500.000.004
2024Q12024-05-16-3.550-1.115-0.3270.000.004
2026Q4---0.505--0.008
2027Q1---0.495--0.004
2027Q2---0.503--0.004
2027Q3---0.498--0.004
2027Q4---0.483---3

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY0.045-0.12550.00-
2024FY-2.180-1.916-1.6340.000.00
2025FY-2.170-2.053-2.1700.006.00
2026FY--1.785--4.29
2027FY--2.096--0.00
2028FY--2.027--0.00
2029FY--2.292--16.67
2030FY--2.553--27.51

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-083010.000.000.00
2026Q4S2026-11-044017.500.0030.00
2026Q4S2026-11-034017.500.0030.00
2026Q4S2026-09-234017.500.0030.00
2026Q4S2026-09-1130110.000.0030.00
2026Q4S2026-07-3131013.770.0030.00
2026Q4S2026-05-0630010.000.0030.00
2026Q4S2026-03-0630010.000.0030.00
2026Q4S2025-11-112000.000.000.00
2026Q4S2025-11-102000.000.000.00
2026Q4S2025-11-092000.000.000.00
2026Q4S2025-11-082000.000.000.00
2026Q4S2025-11-072000.000.000.00
2026Q4S2025-11-062000.000.000.00

Estimate history

EPS, annual-0.9650.125-1.634-2.165-1.7697
Period2022202320242025TTM
EPS, quarterly-0.399-0.563-0.618-0.619-0.455-0.491-0.387-0.404-0.487
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual050000
Period2022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual25.13125.13125.85537.3239.25
Period2022202320242025MRQ
Shares, quarterly25.73625.85525.87225.9229.18337.3237.38637.61339.25
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue0.000.000.0050.000.00
Cost of Goods Sold Incl. D&A0.380.320.260.200.33
Gross Profit-0.38-0.32-0.2649.80-0.33
Selling, General and Administrative Excl. Other72.0367.7450.6433.7322.39
Research and Development52.7151.2038.1627.6016.89
Other Operating Expense0.000.000.000.000.00
Operating Income-72.41-68.06-50.8916.08-22.72
Interest Expense0.000.000.000.210.39
Unusual Expense0.000.000.11-2.871.81
Net Income Before Taxes-63.46-59.98-42.2623.17-24.25
Income Taxes0.000.000.000.450.00
Consolidated Net Income-63.46-59.98-42.2622.72-24.25
Net Income From Continuing Operations-63.46-59.98-42.2622.72-24.25
Net Income-63.46-59.98-42.263.15-24.25
EPS (Recurring)-1.65-2.17-1.630.05-0.91
EPS (Basic, Before Extraordinaries)-1.77-2.17-1.630.13-0.97
EPS (Diluted)-1.77-2.17-1.630.13-0.97
EBITDA-72.03-67.74-50.6416.27-22.39
Non-Operating Income (Expense)8.958.088.744.430.67
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense15.0010.046.801.751.93
Gross Margin---99.61-
Operating Margin---32.15-
Net Margin---6.29-
Shares Outstanding39.2537.3225.8525.1325.13
Market Capitalization414.65414.65377.64373.00-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.080.130.080.090.080.080.080.07
Gross Profit-0.08-0.13-0.08-0.09-0.08-0.08-0.08-0.07
Selling, General and Administrative Excl. Other20.8917.2916.8217.0314.8517.8218.0316.97
Research and Development15.9012.5711.5612.6710.9113.9813.6312.94
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-20.97-17.43-16.90-17.11-14.93-17.90-18.11-17.05
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.00-0.00
Net Income Before Taxes-18.70-15.15-14.46-15.16-12.79-16.04-15.99-14.56
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-18.70-15.15-14.46-15.16-12.79-16.04-15.99-14.56
Net Income From Continuing Operations-18.70-15.15-14.46-15.16-12.79-16.04-15.99-14.56
Net Income-18.70-15.15-14.46-15.16-12.79-16.04-15.99-14.56
EPS (Recurring)-0.49-0.40-0.39-0.49-0.45-0.62-0.62-0.56
EPS (Basic, Before Extraordinaries)-0.49-0.40-0.39-0.49-0.46-0.62-0.62-0.56
EPS (Diluted)-0.49-0.40-0.39-0.49-0.46-0.62-0.62-0.56
EBITDA-20.89-17.29-16.82-17.03-14.85-17.82-18.03-16.97
Non-Operating Income (Expense)2.272.272.451.962.141.862.122.48
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.863.843.822.482.572.422.572.25
Shares Outstanding39.2537.6137.3937.3229.1825.9225.8725.85
Market Capitalization414.65612.76506.17417.53329.49102.71180.58377.64

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments262.90204.76125.1947.24
Short Term Receivables0.000.000.000.00
Inventories0.000.000.000.00
Other Current Assets5.021.632.521.15
Total Current Assets267.92206.39127.7148.39
Net Property, Plant & Equipment8.476.461.402.12
Total Investments and Advances0.000.000.000.00
Deferred Tax Assets1.74---
Other Assets0.260.001.280.13
Total Assets278.38212.85130.3950.64
Short Term Debt Incl. Current Port. of LT Debt2.341.450.465.06
Accounts Payable1.021.810.640.43
Other Current Liabilities6.396.714.382.06
Total Current Liabilities9.749.975.487.55
Long Term Debt5.914.81192.73133.27
Provision for Risks Charges0.000.000.000.00
Deferred Tax Liabilities1.74---
Other Liabilities0.000.000.113.02
Total Liabilities17.3914.78198.32143.85
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00
Common Equity260.99198.07-67.94-93.21
Total Shareholders Equity260.99198.07-67.94-93.21
Accumulated Minority Interest0.000.000.000.00
Total Equity260.99198.07-67.94-93.21
Total Liabilities & Stockholders Equity278.38212.85130.3950.64
Book Value Per Share6.997.66-2.70-3.71
Tangible Book Value Per Share6.997.66-2.70-3.71
Full-Time Employees514131-
Price to Book Ratio1.691.791.77-
Return on Assets-24.42-24.6225.10-
Return on Equity-26.13-64.95--
Return on Invested Capital-22.47-20.8318.21-60.54
Quick Ratio27.5020.6923.296.41
Current Ratio27.5020.6923.296.41

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-63.46-59.98-42.2622.72-24.25
Depreciation0.380.320.260.200.33
Other Funds (Non Cash)16.4510.383.82-2.545.07
Funds from Operations-46.63-49.27-38.1820.37-18.85
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital-5.04-6.045.33-1.02-1.27
Cash from Operating Activities-51.67-55.31-32.8419.35-20.12
Capital Expenditures-0.36-0.23-0.51-0.41-0.12
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.020.000.00
Purchase or Sale of Investments-30.59-3.48-69.25-65.1522.42
Purchase of Investments-243.68-162.50-226.41-141.87-64.70
Sale Or Maturity of Investments213.09159.02157.1676.7187.12
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-30.95-3.71-69.74-65.5722.30
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock115.19112.69109.0059.930.01
Repurchase of Common Pref Stock0.000.000.00-0.03-0.00
Sale of Common Pref Stock115.19112.69109.0059.950.01
Proceedsfrom Stock Options112.88112.47108.2159.800.00
Issuance or Reduction of Debt, Net0.000.000.00-3.75-1.25
Change in Long Term Debt0.000.000.00-3.75-1.25
Issuance of Long Term Debt0.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-3.75-1.25
Net Financing Active Other Cash Flow0.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities115.19112.69109.0056.18-1.24
Net Change in Cash32.5653.666.429.960.94
Free Cash Flow-52.03-55.54-33.3618.93-20.24
Preferred Dividends (Cash Flow)-0.000.00-0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments244.48236.55246.33262.90182.41175.48
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets5.266.036.645.022.521.35
Total Current Assets249.74242.58252.96267.92184.93176.84
Net Property, Plant & Equipment6.947.428.078.475.655.86
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets---1.74--
Other Assets0.300.360.310.260.270.19
Total Assets256.99250.37261.35278.38190.85182.89
Short Term Debt Incl. Current Port. of LT Debt2.722.392.302.341.481.47
Accounts Payable0.640.511.501.020.792.00
Other Current Liabilities4.663.632.866.394.103.75
Total Current Liabilities8.036.536.669.746.367.21
Long Term Debt3.544.184.655.914.024.28
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---1.74--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities11.5710.7111.3117.3910.3811.50
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity245.42239.66250.04260.99180.47171.39
Total Shareholders Equity245.42239.66250.04260.99180.47171.39
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity245.42239.66250.04260.99180.47171.39
Total Liabilities & Stockholders Equity256.99250.37261.35278.38190.85182.89
Book Value Per Share6.256.376.696.996.186.61
Tangible Book Value Per Share6.256.376.696.996.186.61
Full-Time Employees---51--
Price to Book Ratio1.692.451.871.851.780.56
Return on Assets-28.34-26.57-25.43-24.42-29.19-28.13
Return on Equity-29.80-28.01-26.88-26.13-30.40-29.24
Return on Invested Capital-7.51-6.21-5.68-5.68-6.93-9.13
Quick Ratio31.1137.1738.0027.5029.0724.51
Current Ratio31.1137.1738.0027.5029.0724.51

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-18.70-15.15-14.46-15.16-12.79-16.04
Depreciation0.080.130.080.090.080.08
Other Funds (Non Cash)5.993.463.983.022.732.06
Funds from Operations-12.63-11.56-10.39-12.05-9.98-13.90
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.630.01-5.95-0.73-2.29-1.93
Cash from Operating Activities-11.00-11.55-16.34-12.79-12.28-15.84
Capital Expenditures0.00-0.01-0.31-0.04-0.10-0.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments50.954.86-39.00-47.4115.0413.93
Purchase of Investments-16.04-45.78-97.12-84.73-18.64-25.44
Sale Or Maturity of Investments67.0050.6558.1237.3233.6839.37
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities50.954.85-39.31-47.4514.9413.88
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock20.531.250.2093.2119.180.27
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock20.531.250.2093.2119.180.27
Proceedsfrom Stock Options19.430.000.0093.4519.010.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities20.531.250.2093.2119.180.27
Net Change in Cash60.49-5.45-55.4532.9721.85-1.69
Free Cash Flow-11.00-11.56-16.65-12.83-12.38-15.88

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.64%3.7M31.8M828.48K
2026-10-1512.34%3.7M29.6M710.26K
2026-09-3010.36%3.1M29.6M481.48K
2026-09-158.25%2.4M29.6M454.12K
2026-08-317.90%2.3M29.6M429.49K
2026-08-147.89%2.3M29.6M358.24K
2026-07-319.53%2.8M29.6M308.34K
2026-07-158.36%2.4M29.2M315.18K
2026-06-307.31%2.1M29.2M302.07K
2026-06-155.66%1.7M29.2M265.16K
2026-05-294.90%1.4M29.2M273.12K
2026-05-154.85%1.4M29.2M276.05K
2026-04-305.51%1.6M29.2M280.54K
2026-04-1510.65%3.1M29.1M285.52K
2026-03-319.64%2.8M28.8M290.21K
2026-03-139.16%2.6M28.8M244.34K
2026-02-279.48%2.5M26.9M241.85K
2026-02-139.61%2.6M26.9M253.90K
2026-01-309.84%2.6M26.4M236.48K
2026-01-159.82%2.6M26.4M205.64K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.507.309.200.0012.6750.000.000.987-0.0160.001
call5.003.508.000.0010.5100.000.000.976-0.0150.001
call7.501.004.801.155.14051.000.000.956-0.0140.002
call10.000.501.800.972.7061770.000.670-0.0520.006
call12.500.004.000.134.10520.000.000.537-0.1540.007
call15.000.001.000.403.2583600.000.348-0.1130.006
call17.500.003.802.003.7647.000.000.305-0.1170.006
call20.000.003.800.354.2481200.000.285-0.1280.006
call22.500.003.801.354.2881.000.000.235-0.1160.005
call25.000.003.801.904.6244.000.000.225-0.1220.005
call30.000.003.800.055.17816.000.000.210-0.1320.005
put2.500.003.800.006.3180.000.00-0.025-0.0340.001
put5.000.000.150.142.6171060.00-0.025-0.0130.001
put7.500.000.050.057.7212610.00-0.182-0.1900.004
put10.000.200.500.401.30945.009.00-0.325-0.0500.006
put12.500.103.404.603.4143630.00-0.464-0.1550.007
put15.002.056.504.705.22962.000.00-0.652-0.1140.006
put17.504.509.000.005.9580.000.00-0.686-0.1300.006
put20.007.0011.500.006.5090.000.00-0.707-0.1420.006
put22.509.5014.000.006.9410.000.00-0.722-0.1490.006
put25.0012.0016.500.007.3590.000.00-0.733-0.1600.006
put30.0017.0021.500.007.9550.000.00-0.748-0.1720.005

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06SCHEDULE 13G/ASEC
2026-11-05SCHEDULE 13GSEC
2026-11-04144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-10-28SCHEDULE 13GSEC
2026-10-28SCHEDULE 13G/ASEC
2026-10-22SCHEDULE 13GSEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-148-KCurrent report2026-09-14SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-03144Filing for proposed sale of securities under Rule 144.SEC
2026-08-03144Filing for proposed sale of securities under Rule 144.SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-07-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-308-KCurrent report2026-07-30SEC
2026-07-27SCHEDULE 13GSEC
2026-07-17SCHEDULE 13G/ASEC
2026-07-138-KCurrent report2026-07-13SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-08144Filing for proposed sale of securities under Rule 144.SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090041.14K1
2026-080040.03K1
2026-0700188.93K4
2026-0600850.82K4
2026-050054.69K1
2026-040056.01K1
2026-0300116.81K2
2026-0200320.60K8
2026-010094.73K2
2025-120094.57K2
2025-110000

Institutional holders

Manager% owned
MONTANOVA CAPITAL, LLC7.60%
Jupiter Topco LLC7.32%
FMR LLC6.94%
BlackRock, Inc.5.52%
JOHNSON & JOHNSON5.26%
FRANKLIN RESOURCES INC4.92%
BALYASNY ASSET MANAGEMENT L.P.4.07%
VANGUARD CAPITAL MANAGEMENT LLC3.53%
PERCEPTIVE ADVISORS LLC3.36%
MILLENNIUM MANAGEMENT LLC2.49%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.63%
iShares Russell 2000 ETF1.73%
Select Health Care Portfolio1.20%
Franklin Biotechnology Discovery Fund0.88%
VANGUARD EXTENDED MARKET INDEX FUND0.83%
Fidelity Small Cap Index Fund0.79%
Fidelity Advisor Health Care Fund0.75%
iShares Russell 2000 Value ETF0.65%
Fidelity Advisor Biotechnology Fund0.60%
iShares Biotechnology ETF0.55%

OakChart. CTNM. Cached 15 minutes.